Table 2.
Average Percentage Changes (%) in Mean Tumor BF (ml/min per 100 g), BV (ml/100 g), MTT (seconds), PS (ml/min per 100 g), and TV (mm3) Relative to Baseline Values Shown in Table 1 and Average Immunohistochemical End Points for VEGF Expression (Mean Pixel Intensity), MVD (Microvessel Number/mm2), and Apoptosis (CC3-Positive Nuclei/Total Nuclei x 100 [%]) after Treatment with Vandetanib or Vehicle in Nonhypovascular, Hypovascular, and All (Combined) Tumors at 3 to 4 Weeks After Implantation with LoVo Tumor Cells in Nude Rats.
| Group | Treatment | BF | BV | MTT | PS | TV | VEGF | MVD | Apoptosis |
| Nonhypovascular | Vandetanib (n = 5) | -21.37* ± 25.5 | -23.78* ± 20.9 | -0.93 ± 13.2 | -3.28 ± 36.6 | -10.92 ± 11.7 | 34.47 ± 10.8 | 107.40 ± 38.8 | 3.52 ± 0.8 |
| Vehicle (n = 4) | 18.56 ± 19.3 | 50.67 ± 32.3 | 28.95 ± 32.5 | -10.45 ± 43.5 | -3.78 ± 7.6 | 30.91 ± 3.3 | 88.58 ± 46.3 | 3.53 ± 1.2 | |
| Hypovascular | Vandetanib (n = 8) | -10.38 ± 24.1 | -10.31 ± 23.9 | 0.15 ± 10.1 | 1.82 ± 37.7 | -5.49 ± 15.8 | 29.51 ± 8.3 | 55.23 ± 16.5 | 3.59 ± 0.5 |
| Vehicle (n = 4) | -10.04 ± 19.8 | -4.03 ± 11.2 | 9.99 ± 23.7 | 5.30 ± 15.3 | 3.13 ± 23.8 | 30.03 ± 8.5 | 47.96 ± 20.5 | 2.66 ± 0.7 | |
| Combined | Vandetanib (n = 13) | -14.61 ± 24.3 | -15.50† ± 22.9 | -0.26 ± 10.8 | -0.14 ± 35.8 | -7.59 ± 14.1 | 31.42 ± 9.2 | 74.20 ± 36.2 | 3.56 ± 0.6 |
| Vehicle (n = 8) | 4.27 ± 23.7 | 23.30 ± 36.8 | 19.47 ± 28.2 | -2.57 ± 31.3 | -0.32 ± 16.8 | 30.47 ± 6.0 | 68.27 ± 39.0 | 3.10 ± 1.0 |
Values are presented as mean ± SD.
P ≤ .05, different from the relative change in the vehicle-treated rats as determined by the Mann-Whitney U test.
P < .01, different from the relative change in the vehicle-treated rats as determined by the Mann-Whitney U test.